Barclays
ARRY

Barclays’s Array Biopharma Inc ARRY Stock Holding History

Barclays’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-586,743
Closed -$27.2M – 7462
2019
Q2 		$27.2M Buy
586,743
+476,329
+431% +$13.4M 0.02% 763
2019
Q1 		$2.69M Buy
110,414
+87,859
+390% +$1.83M ﹤0.01% 2256
2018
Q4 		$322K Sell
22,555
-81,415
-78% -$1.23M ﹤0.01% 4222
2018
Q3 		$1.58M Buy
103,970
+75,307
+263% +$1.15M ﹤0.01% 3150
2018
Q2 		$481K Sell
28,663
-91,425
-76% -$1.45M ﹤0.01% 3984
2018
Q1 		$1.96M Sell
120,088
-399,624
-77% -$6.4M ﹤0.01% 2483
2017
Q4 		$6.65M Sell
519,712
-290,376
-36% -$3.3M 0.01% 1453
2017
Q3 		$9.96M Buy
810,088
+682,602
+535% +$6.34M 0.01% 1059
2017
Q2 		$1.07M Sell
127,486
-377,030
-75% -$3.08M ﹤0.01% 2830
2017
Q1 		$4.51M Buy
504,516
+439,914
+681% +$4.68M ﹤0.01% 1401
2016
Q4 		$567K Buy
64,602
+61,699
+2,125% +$454K ﹤0.01% 3264
2016
Q3 		$19K Buy
+2,903
New +$11.2K ﹤0.01% 5513
2016
Q2 		– Sell
-12,905
Closed -$26K – 6800
2016
Q1 		$26K Sell
12,905
-53,210
-80% -$159K ﹤0.01% 5118
2015
Q4 		$265K Sell
66,115
-76,401
-54% -$349K ﹤0.01% 3688
2015
Q3 		$570K Sell
142,516
-229,122
-62% -$1.36M ﹤0.01% 3242
2015
Q2 		$2.6M Buy
371,638
+158,049
+74% +$1.17M ﹤0.01% 2011
2015
Q1 		$1.5M Buy
213,589
+6,748
+3% +$48K ﹤0.01% 2589
2014
Q4 		$829K Buy
206,841
+189,580
+1,098% +$750K ﹤0.01% 3371
2014
Q3 		$53K Sell
17,261
-8,027
-32% -$31.6K ﹤0.01% 5845
2014
Q2 		$102K Buy
25,288
+6,101
+32% +$25.2K ﹤0.01% 5398
2014
Q1 		$77K Sell
19,187
-2,488
-11% -$12.5K ﹤0.01% 5662
2013
Q4 		$109K Sell
21,675
-8,535
-28% -$46.5K ﹤0.01% 5578
2013
Q3 		$182K Buy
30,210
+9,676
+47% +$57.5K ﹤0.01% 5137
2013
Q2 		$93K Buy
+20,534
New +$110K ﹤0.01% 5849

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Barclays's ARRY Position: Q3 2019 in Review

Barclays sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 586,743 shares — an estimated $27.2M sold.

Barclays first reported a position in ARRY in Q2 2013 and held it in 24 quarters. The position peaked at $27.2M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Barclays reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Barclays sold 586,743 Array Biopharma Inc shares in Q3 2019, an estimated $27.2M.
  • Barclays first reported a position in Array Biopharma Inc in Q2 2013 and held it in 24 quarters.
  • Barclays's Array Biopharma Inc position peaked at $27.2M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Barclays's 13F filing for Q3 2019, filed 14 Nov 2019.